Format

Send to

Choose Destination
J Dermatolog Treat. 2016;27(3):251-3. doi: 10.3109/09546634.2015.1094179. Epub 2015 Oct 20.

Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.

Author information

1
a Department of Dermatology , University Hospital , Besançon , France .
2
b Department of Dermatology , IBN SINA University Hospital , Rabat , Morocco .
3
c Department of Gastroenterology , University Hospital , Besançon , France .
4
d University of Franche Comté , EA3181 SFR FED 4234 , Besançon , France , and.
5
e Department of Rheumatology , University Hospital , Besançon , France.

Abstract

INTRODUCTION:

Although the efficacy of TNF blockers has been demonstrated in hidradenitis suppurativa (HS), many paradoxical effects have also been described with TNF antagonists. We wished to describe patients with adalimumab (ADA)-induced paradoxical HS.

METHODS:

This is a retrospective descriptive case series of four patients with ADA-induced paradoxical HS.

RESULTS:

All the patients had a good response to TNFa antagonist therapy at the time of HS occurrence. The time from TNFa antagonist initiation to HS onset or exacerbation ranged from a few weeks to 24 months. The outcome of HS was variable. Systemic antibiotics were required in all the cases to control HS. TNF blockers were continued in three cases with a switch to another anti-TNF class in one case. Switch to ustekinumab was prescribed in one patient with SA and Crohn's disease.

CONCLUSION:

Although the imputability of TNF blockers in paradoxical HS is still debatable, further research and observation are needed to confirm and distinguish patients with genetic and clinical predisposition in the onset or exacerbation of HS during anti-TNF treatment.

KEYWORDS:

adalimumab; adverse effect; anti-TNF; hidradenitis suppurativa; paradoxical reaction

PMID:
26368546
DOI:
10.3109/09546634.2015.1094179
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center